Patents by Inventor Qingming Zhu

Qingming Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diacylglycerol kinase modulating compounds
    Patent number: 11845723
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: December 19, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Masaaki Sawa, Mai Arai, Ryoko Nakai, Hirokazu Matsumoto, Catherine Pugh, Eric Hu, Juan Guerrero, Jesse Jacobsen, Jonathan William Medley, Jie Xu, Latesh Lad, Leena Patel, Michael Graupe, Qingming Zhu, Stephen Holmbo, Tetsuya Kobayashi, Will Watkins, Yasamin Moazami, Suet C. Yeung, Julian A. Codelli, Heath A. Weaver
  • MCL1 INHIBITORS
    Publication number: 20230348494
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: March 9, 2023
    Publication date: November 2, 2023
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, Qingming Zhu
  • MCL1 inhibitors
    Patent number: 11667652
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • DIACYLGLYERCOL KINASE MODULATING COMPOUNDS
    Publication number: 20230060354
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Application
    Filed: June 21, 2022
    Publication date: March 2, 2023
    Inventors: Julian A. Codelli, Michael Graupe, Juan A. Guerrero, Stephen D. Holmbo, Tetsuya Kobayashi, Yasamin Moazami, Leena B. Patel, Heath A. Weaver, Jie Xu, Suet C. Yeung, QingMing Zhu
  • DIACYLGLYCEROL KINASE MODULATING COMPOUNDS
    Publication number: 20220324866
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Application
    Filed: December 18, 2020
    Publication date: October 13, 2022
    Inventors: Masaaki SAWA, Mai ARAI, Ryoko NAKAI, Hirokazu MATSUMOTO, Catherine PUGH, Eric HU, Juan GUERRERO, Jesse JACOBSEN, Jonathan William MEDLEY, Jie XU, Latesh LAD, Leena PATEL, Michael GRAUPE, Qingming ZHU, Stephen HOLMBO, Tetsuya KOBAYASHI, Will WATKINS, Yasamin MOAZAMI, Suet C. YEUNG, Julian A. CODELLI, Heath A. WEAVER
  • MCL1 INHIBITORS
    Publication number: 20210171543
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: November 10, 2020
    Publication date: June 10, 2021
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20200276169
    Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.
    Type: Application
    Filed: March 19, 2020
    Publication date: September 3, 2020
    Inventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
  • Beta-lactamase inhibitors
    Patent number: 10597396
    Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 24, 2020
    Assignee: Novartis AG
    Inventors: Anthony Casarez, Markus Furegati, Guido Koch, Xiaodong Lin, Flavio Ossola, Folkert Reck, Robert Lowell Simmons, Qingming Zhu
  • Monobactam organic compounds for the treatment of bacterial infections
    Patent number: 10369138
    Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: August 6, 2019
    Assignee: Novartis AG
    Inventors: Virender Singh Aulakh, Anthony Casarez, Xiaodong Lin, Mika Lindvall, Glenn McEnroe, Heinz Ernst Moser, Folkert Reck, Meiliana Tjandra, Robert Lowell Simmons, Aregahegn Yifru, Qingming Zhu
  • MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20190231752
    Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Inventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20190177324
    Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.
    Type: Application
    Filed: September 28, 2017
    Publication date: June 13, 2019
    Applicant: Novartis AG
    Inventors: Anthony CASAREZ, Markus FUREGATI, Guido KOCH, Xiaodong LIN, Flavio OSSOLA, Folkert RECK, Robert Lowell SIMMONS, Qingming ZHU
  • Beta-lactamase inhibitors
    Patent number: 10065957
    Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 4, 2018
    Assignee: Novartis AG
    Inventors: Anthony Casarez, Markus Furegati, Guido Koch, Xiaodong Lin, Flavio Ossola, Folkert Reck, Robert Lowell Simmons, Qingming Zhu
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20180086762
    Abstract: This invention pertains generally to compounds of Formula (A), as further described herein, which act as beta-lactamase inhibitors, and salts, crystalline forms and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds in combination with a beta-lactam antibiotic to treat infections caused by Gram-negative bacteria, including drug-resistant strains.
    Type: Application
    Filed: September 28, 2017
    Publication date: March 29, 2018
    Inventors: Anthony CASAREZ, Markus FUREGATI, Guido KOCH, Xiaodong LIN, Flavio OSSOLA, Folkert RECK, Robert Lowell SIMMONS, Qingming ZHU
  • MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20160051523
    Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.
    Type: Application
    Filed: September 22, 2015
    Publication date: February 25, 2016
    Applicant: NOVARTIS AG
    Inventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
  • Monobactam organic compounds for the treatment of bacterial infections
    Patent number: 9174978
    Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: November 3, 2015
    Assignee: Novartis AG
    Inventors: Virender Singh Aulakh, Anthony Casarez, Xiaodong Lin, Mika Lindvall, Glenn McEnroe, Heinz Ernst Moser, Folkert Reck, Meiliana Tjandra, Robert Lowell Simmons, Aregahegn Yifru, Qingming Zhu
  • MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20150266867
    Abstract: This invention pertains generally to antibacterial compounds of Formula I, as further described herein, and pharmaceutically acceptable salts and formulations thereof. In certain aspects, the invention pertains to methods of using such compounds to treat infections such as those caused by Gram-negative bacteria.
    Type: Application
    Filed: March 23, 2015
    Publication date: September 24, 2015
    Applicant: NOVARTIS AG
    Inventors: Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Meiliana TJANDRA, Robert Lowell SIMMONS, Aregahegn YIFRU, Qingming ZHU
  • Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders
    Patent number: 8207172
    Abstract: The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: June 26, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Chengzhi Zhang, Jacques Dumas, Qingming Zhu, Roger Smith, Qingjie Liu, Sharad Verma, Jason Duquette, Qian Zhao, Dongping Fan, Georgiy Bondar, Philip Coish
  • Bicyclic urea derivatives useful in the treatment of cancer and other disorders
    Patent number: 8076488
    Abstract: This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: December 13, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, Stephen Boyer, Sharad Verma, Lila Adnane, Yuanwei Chen, Wendy Lee, Barton Phillips, Roger A. Smith, William J. Scott, Jennifer Burke, Jianqing Chen, Zhi Chen, Jianmei Fan, Karl Miranda, Brian Raudenbush, Aniko Redman, Jianxing Shao, Ning Su, Gan Wang, Lin Yi, Qingming Zhu
  • NOVEL HETEROCYCLES
    Publication number: 20110172224
    Abstract: The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.
    Type: Application
    Filed: August 19, 2005
    Publication date: July 14, 2011
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Chengzhi Zhang, Jacques Dumas, Qingming Zhu, Roger Smith, Qingjie Liu, Sharad Verma, Jason Duquette, Qian Zhao, Dongping Fan, Georgiy Bondar, Philip Coish
  • ORGANIC COMPOUNDS
    Publication number: 20110092505
    Abstract: The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 12, 2009
    Publication date: April 21, 2011
    Inventors: Robin Burgis, Michael Paul Capparelli, Lucian Dipietro, Gabriel G. Gamber, Charles Francis Jewell, JR., Erik Meredith, Karl Miranda, Lauren G. Monovich, Chang Rao, Nicolas Soldermann, Taeyoung Yoon, Qingming Zhu